Lacirex

Lacidipine, the active ingredient in Lacirex, is a calcium channel blocker presented as an oral dosage form for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Lacirex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is a dihydropyridine calcium channel blocker indicated for the management of high blood pressure. - Hypertension: lowers systemic vascular resistance and reduces elevated blood pressure, helping to prevent cardiovascular complications.

Lacidipine may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs. - Dizziness: especially upon standing. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat. - Elevated liver enzymes: indicating possible hepatic involvement. - Cardiac arrhythmia: irregular heart rhythm.

When prescribing lacidipine, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Sudden discontinuation: taper gradually to avoid rebound hypertension. - Cardiovascular disease: evaluate risk of ischemic events. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Concurrent use with other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood pressure lowering. - Diuretics: may enhance orthostatic hypotension. - NSAIDs: can blunt antihypertensive response. - Grapefruit juice: may modestly raise drug concentrations. - Alcohol: can increase dizziness and hypotensive effects.